Preliminary pharmacology of galactosylated chitosan/5-fluorouracil nanoparticles and its inhibition of hepatocellular carcinoma in mice

References

• Kim NH, Kim SN, Oh JS, Lee S, Kim YK. Anti-mitotic potential of 7-diethylamino-3(2′-benzoxazolyl)-coumarin in 5-fluorouracil-resistant human gastric cancer cell line SNU620/5-FU. Biochem Biophys Res Commun 2012; 418:616 - 21; http://dx.doi.org/10.1016/j.bbrc.2012.01.049; PMID: 22301191
   PubMed Web of Science ®Google Scholar
• Hsieh CH, Liu CY, Hsieh YJ, Tai HC, Wang LY, Tsai TH, et al. Matrix metalloproteinase-8 mediates the unfavorable systemic impact of local irradiation on pharmacokinetics of anti-cancer drug 5-Fluorouracil. PLoS One 2011; 6:e21000; http://dx.doi.org/10.1371/journal.pone.0021000; PMID: 21695264
   PubMedGoogle Scholar
• Namikawa T, Fukudome I, Kitagawa H, Okabayashi T, Kobayashi M, Hanazaki K. Plasma diamine oxidase activity is a useful biomarker for evaluating gastrointestinal tract toxicities during chemotherapy with oral fluorouracil anti-cancer drugs in patients with gastric cancer. Oncology 2012; 82:147 - 52; http://dx.doi.org/10.1159/000336799; PMID: 22433290
   PubMed Web of Science ®Google Scholar
• Sakata Y, Komatsu Y, Takagi S, Saitoh S, Itoh T, Suzuki H, et al. Randomized controlled study of mitomycin C/carboquone/5-fluorouracil/OK-432 (MQ-F-OK) therapy and mitomycin C/5-fluorouracil/doxorubicin (FAM) therapy against advanced liver cancer. Cancer Chemother Pharmacol 1989; 23:Suppl S9 - 12; http://dx.doi.org/10.1007/BF00647230; PMID: 2647315
   PubMed Web of Science ®Google Scholar
• Kanetaka K, Enjoji A, Furui J, Nagata Y, Fujioka H, Shiogama T, et al, The Nagasaki Study Group for Digestive Organ Cancer Chemotherapy. Effects of Intermittent 5-Fluorouracil and Low-dose Cisplatin Therapy on Advanced and Recurrent Gastric Cancer. Anticancer Res 2012; 32:3495 - 9; PMID: 22843936
   PubMed Web of Science ®Google Scholar
• Sinha VR, Honey. Critical aspects in rationale design of fluorouracil-based adjuvant therapies for the management of colon cancer. Crit Rev Ther Drug Carrier Syst 2012; 29:89 - 148; http://dx.doi.org/10.1615/CritRevTherDrugCarrierSyst.v29.i2.10; PMID: 22577701
   PubMed Web of Science ®Google Scholar
• Kurosaki I, Kawachi Y, Nihei K, Tsuchiya Y, Aono T, Yokoyama N, et al. Liver perfusion chemotherapy with 5-Fluorouracil followed by systemic gemcitabine administration for resected pancreatic cancer: preliminary results of a prospective phase 2 study. Pancreas 2009; 38:161 - 7; http://dx.doi.org/10.1097/MPA.0b013e31818815f7; PMID: 18797423
   PubMed Web of Science ®Google Scholar
• Zhao HY, Huang H, Hu ZH, Huang Y, Lin SX, Tian Y, et al. Evaluations of biomarkers associated with sensitivity to 5-fluorouracil and taxanes for recurrent/advanced breast cancer patients treated with capecitabine-based first-line chemotherapy. Anticancer Drugs 2012; 23:534 - 42; http://dx.doi.org/10.1097/CAD.0b013e32834f7ef4; PMID: 22481060
   PubMed Web of Science ®Google Scholar
• White RM. Correct fluorouracil (5-FU) half-life comparator for a 5-FU prodrug plus a dihydropyrimidine dehydrogenase inhibitor. J Clin Oncol 2001; 19:2970; PMID: 11387375
   PubMed Web of Science ®Google Scholar
• Dikken C, Sitzia J. Patients’ experiences of chemotherapy: side-effects associated with 5-fluorouracil + folinic acid in the treatment of colorectal cancer. J Clin Nurs 1998; 7:371 - 9; http://dx.doi.org/10.1046/j.1365-2702.1998.00159.x; PMID: 9830978
   PubMed Web of Science ®Google Scholar
• Wettergren Y, Carlsson G, Odin E, Gustavsson B. Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy. Cancer 2012; 118:2935 - 43; http://dx.doi.org/10.1002/cncr.26595; PMID: 22020693
   PubMed Web of Science ®Google Scholar
• Wilson B, Ambika TV, Dharmesh Kumar Patel R, Jenita JL, Priyadarshini SR. Nanoparticles based on albumin: Preparation, characterization and the use for 5-flurouracil delivery. Int J Biol Macromol 2012; http://dx.doi.org/10.1016/j.ijbiomac.2012.07.014; PMID: 22820011
   PubMed Web of Science ®Google Scholar
• Chandy T, Das GS, Rao GH. 5-Fluorouracil-loaded chitosan coated polylactic acid microspheres as biodegradable drug carriers for cerebral tumours. J Microencapsul 2000; 17:625 - 38; http://dx.doi.org/10.1080/026520400417676; PMID: 11038121
   PubMed Web of Science ®Google Scholar
• Zhu L, Ma J, Jia N, Zhao Y, Shen H. Chitosan-coated magnetic nanoparticles as carriers of 5-fluorouracil: preparation, characterization and cytotoxicity studies. Colloids Surf B Biointerfaces 2009; 68:1 - 6; http://dx.doi.org/10.1016/j.colsurfb.2008.07.020; PMID: 19013060
   PubMed Web of Science ®Google Scholar
• Lai LF, Guo HX. Preparation of new 5-fluorouracil-loaded zein nanoparticles for liver targeting. Int J Pharm 2011; 404:317 - 23; http://dx.doi.org/10.1016/j.ijpharm.2010.11.025; PMID: 21094232
   PubMed Web of Science ®Google Scholar
• Lai LF, Guo HX. Preparation of new 5-fluorouracil-loaded zein nanoparticles for liver targeting. Int J Pharm 2011; 404:317 - 23; http://dx.doi.org/10.1016/j.ijpharm.2010.11.025; PMID: 21094232
   PubMed Web of Science ®Google Scholar
• Kim TH, Park IK, Nah JW, Choi YJ, Cho CS. Galactosylated chitosan/DNA nanoparticles prepared using water-soluble chitosan as a gene carrier. Biomaterials 2004; 25:3783 - 92; http://dx.doi.org/10.1016/j.biomaterials.2003.10.063; PMID: 15020154
   PubMed Web of Science ®Google Scholar
• Fallon RJ, Danaher M, Saxena A. The asialoglycoprotein receptor is associated with a tyrosine kinase in HepG2 cells. J Biol Chem 1994; 269:26626 - 9; PMID: 7929394
   PubMed Web of Science ®Google Scholar
• Cheng M, Li Q, Wan T, Hong X, Chen H, He B, et al. Synthesis and efficient hepatocyte targeting of galactosylated chitosan as a gene carrier in vitro and in vivo. J Biomed Mater Res B Appl Biomater 2011; 99:70 - 80; http://dx.doi.org/10.1002/jbm.b.31873; PMID: 21656667
   PubMed Web of Science ®Google Scholar
• Chang CJ, Chen YH, Huang KW, Cheng HW, Chan SF, Tai KF, et al. Combined GM-CSF and IL-12 gene therapy synergistically suppresses the growth of orthotopic liver tumors. Hepatology 2007; 45:746 - 54; http://dx.doi.org/10.1002/hep.21560; PMID: 17326190
   PubMed Web of Science ®Google Scholar
• Wang XH, Liu BR, Qu B, Xing H, Gao SL, Yin JM, et al. Silencing STAT3 may inhibit cell growth through regulating signaling pathway, telomerase, cell cycle, apoptosis and angiogenesis in hepatocellular carcinoma: potential uses for gene therapy. Neoplasma 2011; 58:158 - 71; http://dx.doi.org/10.4149/neo_2011_02_158; PMID: 21275467
   PubMed Web of Science ®Google Scholar
• Dung TD, Chang HC, Chen CY, Peng WH, Tsai CH, Tsai FJ, et al. Zanthoxylum avicennae extracts induce cell apoptosis through protein phosphatase 2A activation in HA22T human hepatocellular carcinoma cells and block tumor growth in xenografted nude mice. Int J Mol Med 2011; 28:927 - 36; PMID: 21874223
   PubMed Web of Science ®Google Scholar
• Khurana A, McKean H, Kim H, Kim SH, McGuire J, Roberts LR, et al. Silencing of HSulf-2 expression in MCF10DCIS.com cells attenuate ductal carcinoma in situ progression to invasive ductal carcinoma in vivo. Breast Cancer Res 2012; 14:R43; http://dx.doi.org/10.1186/bcr3140; PMID: 22410125
   PubMedGoogle Scholar
• Li DC, Zhong XK, Zeng ZP, Jiang JG, Li L, Zhao MM, et al. Application of targeted drug delivery system in Chinese medicine. J Control Release 2009; 138:103 - 12; http://dx.doi.org/10.1016/j.jconrel.2009.05.008; PMID: 19433120
   PubMed Web of Science ®Google Scholar
• Whitesides GM. The ‘right’ size in nanobiotechnology. Nat Biotechnol 2003; 21:1161 - 5; http://dx.doi.org/10.1038/nbt872; PMID: 14520400
   PubMed Web of Science ®Google Scholar
• Marcucci F, Lefoulon F. Active targeting with particulate drug carriers in tumor therapy: fundamentals and recent progress. Drug Discov Today 2004; 9:219 - 28; http://dx.doi.org/10.1016/S1359-6446(03)02988-X; PMID: 14980540
   PubMed Web of Science ®Google Scholar
• Alex SM, Rekha MR, Sharma CP. Spermine grafted galactosylated chitosan for improved nanoparticle mediated gene delivery. Int J Pharm 2011; 410:125 - 37; http://dx.doi.org/10.1016/j.ijpharm.2011.02.067; PMID: 21396993
   PubMed Web of Science ®Google Scholar
• Jiang H, Wu H, Xu YL, Wang JZ, Zeng Y. Preparation of galactosylated chitosan/tripolyphosphate nanoparticles and application as a gene carrier for targeting SMMC7721 cells. J Biosci Bioeng 2011; 111:719 - 24; http://dx.doi.org/10.1016/j.jbiosc.2011.01.012; PMID: 21334972
   PubMed Web of Science ®Google Scholar
• Kim JH, Kim YS, Park K, Lee S, Nam HY, Min KH, et al. Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice. J Control Release 2008; 127:41 - 9; http://dx.doi.org/10.1016/j.jconrel.2007.12.014; PMID: 18234388
   PubMed Web of Science ®Google Scholar
• Yu BT, Sun X, Zhang ZR. Enhanced liver targeting by synthesis of N1-stearyl-5-Fu and incorporation into solid lipid nanoparticles. Arch Pharm Res 2003; 26:1096 - 101; http://dx.doi.org/10.1007/BF02994764; PMID: 14723346
   PubMed Web of Science ®Google Scholar
• Yan C, Gu J, Guo Y, Chen D. In vivo biodistribution for tumor targeting of 5-fluorouracil (5-FU) loaded N-succinyl-chitosan (Suc-Chi) nanoparticles. Yakugaku Zasshi 2010; 130:801 - 4; http://dx.doi.org/10.1248/yakushi.130.801; PMID: 20519858
   PubMed Web of Science ®Google Scholar
• Sasaki K, Tsuno NH, Sunami E, Tsurita G, Kawai K, Okaji Y, et al. Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells. BMC Cancer 2010; 10:370; http://dx.doi.org/10.1186/1471-2407-10-370; PMID: 20630104
   PubMed Web of Science ®Google Scholar
• Huang Z, Guo KJ, Guo RX, He SG. Effects of 5-fluouracil combined with sulfasalazine on human pancreatic carcinoma cell line BxPC-3 proliferation and apoptosis in vitro. Hepatobiliary Pancreat Dis Int 2007; 6:312 - 20; PMID: 17548258
   PubMed Web of Science ®Google Scholar